CST2

Across TCGA pan-cancer cohorts, CST2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated CST2 data layer compared with 6 for mutation status.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CST2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CST2 expression acts as an unfavorable survival marker, although some lineages such as BRCA and ESCA show a favorable association.

KIRP, KIRC, and SKCM are the cancer types where CST2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Tertile	All	0.852	0.971	<.001	121	view →
KIRC	OS	Median	All	0.554	0.703	<.001	96	view →
SKCM	OS	Tertile	All	0.733	0.856	<.001	82	view →
BRCA	OS	Median	III,IV	0.957	0.850	<.001	64	view →
OV	DFS	Tertile	IV	0.271	0.515	.007	50	view →
GBM	OS	Tertile	All	0.308	0.485	<.001	36	view →
ACC	DFS	Quartile	III,IV	0.168	0.661	.003	32	view →
LGG	DFS	Tertile	All	0.258	0.492	<.001	30	view →
STAD	OS	Tertile	All	0.484	0.669	<.001	26	view →
LUSC	OS	Tertile	All	0.298	0.477	.003	21	view →
ESCA	OS	Quartile	III,IV	0.740	0.423	.008	20	view →
MESO	DFS	Tertile	IV	0.803	0.317	.033	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

CST2–KIRP (OS)

Open the KIRP breakdown →